RxDoctor Payments Data

Timothy Miller, MD

Internal Medicine · Temple, TXNPI 1346419355

Payments from drug & device makers

$145,515in general payments, 2019–2025

Across 822 payments — averaging $177.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$77K
  • Phathom Pharmaceuticals, Inc.$29K
  • Madrigal Pharmaceuticals$17K
  • Aimmune Therapeutics, Inc.$9K
  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • plus $7K from 43 others

What the payments were for

  • Consulting fees$9751%
  • Speaking & faculty fees$124,20685%
  • Travel & lodging$2,5662%
  • Food & beverage$16,60711%
  • Education$1,1601%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$145,515 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$267,646
Medicare patients
793
Services billed
6,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$467,051
EpclusaSofosbuvir/Velpatasvir12$293,213
XifaxanRifaximin67$218,453
SimponiGolimumab12$83,876
Humira(Cf) PenAdalimumab12$78,140
LinzessLinaclotide68$65,308
CreonLipase/Protease/Amylase20$57,043
Dexlansoprazole DrDexlansoprazole86$23,837
VemlidyTenofovir Alafenamide14$18,428
Omeprazole561$11,958
Mesalamine24$10,498
Esomeprazole Magnesium77$8,697
Budesonide DrBudesonide62$6,995
Pantoprazole Sodium403$5,787
Sucralfate72$5,604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Simponi$1,207$550,92729 claims
GileadEpclusa, Vemlidy$545$311,64126 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$905$218,45367 claims
AbbVieLinzess, Creon$3,611$122,35188 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →